Mai Capital Management Syndax Pharmaceuticals Inc Call Options Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SNDX
# of Institutions
241Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$83.9 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$77.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$48 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$41.5 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$39.5 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $557M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...